Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 23 of 23
MOLECULAR VIROLOGY: ADVANCES IN THE UNDERSTANDING OF HIV-1
Paul Bieniasz
Howard Hughes Medical Center, New York, NY, USA
from CROI 2017 on February 13, 2017 9:00 AM-12:15 PM
ADVANCES IN ANTIBODIES
Richard A Koup
VRC, NIAID, NIH, Bethesda, MD, USA
from CROI 2017 on February 13, 2017 9:00 AM-12:15 PM
ADVANCES IN HIV PREVENTION: NEW BIOMEDICAL AND BEHAVIORAL APPROACHES
James A McIntyre
Anova Health Institute, Johannesburg, South Africa
from CROI 2017 on February 13, 2017 9:00 AM-12:15 PM
HIV COMPLICATIONS: PERSISTENT THREAT OR A PROBLEM OF THE PAST?
Judith S Currier
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2017 on February 13, 2017 9:00 AM-12:15 PM
HIV RESERVOIRS: OBSTACLES TO AN HIV CURE
Nicolas Chomont
Université de Montréal, Montreal, QC, Canada
from CROI 2017 on February 13, 2017 9:00 AM-12:15 PM
MARTIN DELANEY PRESENTATION: FROM LAB TO LICENSURE: THE IMPORTANCE OF GOOD PARTICIPATORY PRACTICE (GPP) IN RESEARCH
MODERATOR
Mark Hubbard
Tennessee Association of People with AIDS, Nashville, TN, USA
HISTORY AND PRINCIPLES OF GOOD PARTICIPATORY PRACTICE GUIDELINES
Stacey Hannah
AIDS Vaccine Advocacy Coalition, New York, NY, USA
GPP AS A GUIDE TO BIOMEDICAL HIV PREVENTION TRIAL DESIGN AND IMPLEMENTATION
Deborah Baron
Wits RHI, Johannesburg, South Africa
APPLYING GPP PRINCIPLES TO CURE RESEARCH
David Evans
Project Inform, San Francisco, CA, USA
QUESTIONS AND ANSWERS
from CROI 2017 on February 13, 2017 12:15 PM-1:45 PM
PREVENTION TRIAL DESIGN IN THE ERA OF PREP
Deborah J Donnell
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
IMPLEMENTATION SCIENCE TRIALS: DO THE RULES OF RCTS APPLY?
James R Hargreaves
London School of Hygiene and Tropical Medicine, London, United Kingdom
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
RESPONDENT DRIVEN SAMPLING & OTHER METHODS FOR RECRUITING HARD TO REACH POPULATIONS
Carl A Latkin
Johns Hopkins University, Baltimore, MD, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
HIGH-THROUGHPUT GENOME ENGINEERING IN PRIMARY CD4+ T CELLS
Judd F Hultquist
University of California, San Francisco, San Francisco, CA, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
IDENTIFYING AND PROFILING VIRUS-SPECIFIC T CELLS USING MASS CYTOMETRY
Evan William Newell
Singapore Immunology Network, Singapore, Singapore
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
QUANTIFYING HIV-1 MRNA STRUCTURE AND TRANSLATION EFFICIENCY IN CELLS
Silvi Rouskin
Whitehead Institute, Cambridge, MA, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
APPROACHES TO STAGING AND TREATMENT OF EARLY STAGE HCV
John D Scott
University of Washington, Seattle, WA, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
EFFECT OF RAVs ON DAA TREATMENT AND RE-TREATMENT OF PTS WITH CHRONIC HCV INFECTION
Alessandra Mangia
Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
COMMON DRUG INTERACTIONS WITH HIV/HCV COINFECTION
Debika Bhattacharya
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
CIRRHOSIS ISSUES
Sanjay Bhagani
Royal Free Hospital, London, United Kingdom
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
QUESTIONS AND ANSWERS
from CROI 2017 on February 13, 2017 2:15 PM-4:00 PM
WELCOME AND OVERVIEW OF CROI 2017
Susan P. Buchbinder
CROI Chair and University of California, San Francisco, CA, USA
Judith Currier
CROI Vice Chair and University of California, Los Angeles, CA, USA
Richard Koup
CROI Vice Chair and National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
from CROI 2017 on February 13, 2017 3:00 PM-3:45 PM
DISCUSSION OF ORAL ABSTRACT SESSION 4 – NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
CHAIR
Joseph Eron
University of North Carolina, Chapel Hill, NC, USA
OA4: DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
Winston Tse
Gilead Scis, Inc, Foster City, CA, USA
OA4: RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
Paul Sax
Brigham and Women's Hosp, Boston, MA, USA
OA4: PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
Anne Derache
Africa Hlth Rsr Inst, Mtubatuba, South Africa
OA4: PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
Josep M. Llibre
Univ Hosp Germans Trias, Badalona, Barcelona, Spain
from CROI 2017 on February 13, 2017 3:00 PM-3:45 PM
OPENING SESSION HOST
Susan P Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2017 on February 13, 2017 5:00 PM-7:00 PM
BERNARD FIELDS LECTURE: INSIGHTS INTO HIV PREVENTION, PATHOGENESIS, AND TREATMENT FROM NONHUMAN PRIMATE MODELS
Jeffrey D Lifson
Frederick National Laboratory, Frederick, MD, USA
from CROI 2017 on February 13, 2017 5:00 PM-7:00 PM
N'GALY-MANN LECTURE: HIV/AIDS RESEARCH IN ZIMBABWE: PROVIDING THE EVIDENCE FOR QUALITY CARE
James G. Hakim
University of Zimbabwe, Harare, Zimbabwe
from CROI 2017 on February 13, 2017 5:00 PM-7:00 PM
CROI FOUNDATION SPECIAL EVENT: MUSICAL PERFORMANCE BY ZIMBABWEAN HUMAN RIGHTS ACTIVIST OLIVER MTUKUDZI AND HIS BAND, THE BLACK SPIRITS
from CROI 2017 on February 13, 2017 5:00 PM-7:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 23 of 23